手術による切除が不可能で、他の部位への転移がある可能性のある進行性肝細胞癌(HCC)の成人患者を対象に、PF-08634404という研究薬を単剤療法および併用療法として投与する試験
PF-08634404を切除不能な局所進行または転移性肝細胞癌を有する成人参加者における単剤療法および併用療法としての安全性、薬物動態、および予備的有効性を評価するための介入的オープンラベル第1b相/第2相試験
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
- Be 18 years or older.
- Have locally advanced or metastatic HCC.
- Is not a candidate for complete surgical or loco-regional therapies.
- Have not received any whole-body treatment for HCC.
Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
California
-
Irvine、California、アメリカ、92612
- 募集
- Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Irvine、California、アメリカ、92612
- 募集
- UCI Health - Irvine Infusion Pharmacy ACC
-
Irvine、California、アメリカ、92612
- 募集
- UCI Health - Irvine
-
Los Angeles、California、アメリカ、90033
- 募集
- USC/Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90033
- 募集
- Keck Hospital of USC
-
Los Angeles、California、アメリカ、90033
- 募集
- USC/Norris Comprehensive Cancer Center / Investigational Drug Services
-
Los Angeles、California、アメリカ、90033
- 募集
- Los Angeles General Medical Center
-
Los Angeles、California、アメリカ、90025
- 募集
- START Los Angeles, LLC
-
Los Angeles、California、アメリカ、90067
- 募集
- LACN Century City
-
Orange、California、アメリカ、92868
- 募集
- UC Irvine Health - Chao Family Comprehensive Cancer Center
-
Pasadena、California、アメリカ、91105
- 募集
- Keck Medical Center of USC Pasadena
-
-
Florida
-
Land O' Lakes、Florida、アメリカ、34638
- 募集
- Moffitt Cancer Center at Speros
-
Ruskin、Florida、アメリカ、33570
- 募集
- Moffitt Cancer Center at SouthShore
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center - McKinley Campus
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt McKinley Hospital
-
Tampa、Florida、アメリカ、33607
- 募集
- Moffitt Cancer Center - International Plaza
-
Wesley Chapel、Florida、アメリカ、33544
- 募集
- Moffitt Cancer Center at Wesley Chapel
-
-
Illinois
-
Shiloh、Illinois、アメリカ、62269
- 募集
- Siteman Cancer Center - Shiloh
-
Shiloh、Illinois、アメリカ、62269
- 募集
- Memorial Hospital
-
-
Minnesota
-
Coon Rapids、Minnesota、アメリカ、55433
- 募集
- Allina Health Cancer Institute - Mercy Hospital
-
Minneapolis、Minnesota、アメリカ、55407
- 募集
- Allina Health Cancer Institute - Abbott Northwestern Hospital
-
Saint Paul、Minnesota、アメリカ、55102
- 募集
- Allina Health Cancer Institute - United Hospital
-
-
Missouri
-
City of Saint Peters、Missouri、アメリカ、63376
- 募集
- Siteman Cancer Center - St. Peters
-
Creve Coeur、Missouri、アメリカ、63141
- 募集
- Siteman Cancer Center - West County
-
Florissant、Missouri、アメリカ、63031
- 募集
- Siteman Cancer Center - North County
-
Kansas City、Missouri、アメリカ、64111
- 募集
- Saint Luke's Hospital of Kansas City
-
Kansas City、Missouri、アメリカ、64111
- 募集
- Saint Luke's Cancer Institute
-
St Louis、Missouri、アメリカ、63108
- 募集
- Siteman Cancer Center
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine - Siteman Cancer Center
-
St Louis、Missouri、アメリカ、63110
- 募集
- Barnes-Jewish Hospital
-
St Louis、Missouri、アメリカ、63129
- 募集
- Siteman Cancer Center - South County
-
-
Nevada
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Regional Medical Center
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Health Medical Oncology
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Office of Clinical Research
-
-
North Carolina
-
Cary、North Carolina、アメリカ、27518
- 募集
- Duke Cancer Center Cary
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke Cancer Center
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University - Main Hospital and Clinics
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke Cancer Center - Investigational Chemotherapy Service
-
Raleigh、North Carolina、アメリカ、27609
- 募集
- Duke Cancer Center Raleigh
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- 募集
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15212
- 募集
- AHN Allegheny General Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15212
- 募集
- AHN Cancer Institute at Allegheny General Hospital
-
-
Washington
-
Seattle、Washington、アメリカ、98101
- 募集
- Virginia Mason Medical Center
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Center
-
Seattle、Washington、アメリカ、98195
- 募集
- University of Washington Medical Center- Montlake
-
-
-
-
-
San Juan、プエルトリコ、00909
- 募集
- Pan American Center for Oncology Trials, LLC
-
-
United States of America
-
Dorado、United States of America、プエルトリコ、00646
- 募集
- Pan American Center for Oncology Trials, LLC - Dorado Office
-
Mayagüez、United States of America、プエルトリコ、00680
- 募集
- Pan American Center for Oncology Trials, LLC - Mayaguez Office
-
Ponce、United States of America、プエルトリコ、00730
- 募集
- Pan American Center for Oncology Trials, LLC - Ponce Office
-
-
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 募集
- Zhongshan Hospital,Fudan University
-
-
-
-
-
Taichung、台湾、407
- 募集
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- 募集
- National Cheng Kung University Hospital
-
Taipei、台湾、10002
- 募集
- National Taiwan University Hospital
-
Taipei、台湾、112
- 募集
- Taipei Veterans General Hospital
-
-
-
-
-
Fukuoka、日本、811-1395
- 募集
- National Hospital Organization Kyushu Cancer Center
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- 募集
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa、Chiba、日本、277-8577
- 募集
- National Cancer Center Hospital East
-
-
Osaka
-
Sakai、Osaka、日本、590-0197
- 募集
- Kindai University Hospital- Osaka Medical Campus
-
-
Tokyo
-
Chuo-ku、Tokyo、日本、104-0045
- 募集
- National Cancer Center Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 years of age or older at screening.
- Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
- Adequate hepatic, liver, and renal function
- No prior systemic therapy for HCC.
- ECOG performance status 0 or 1
- Child-Pugh Class A
Key Exclusion Criteria:
- Moderate or severe ascites.
- History of hepatic encephalopathy.
- Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
- Clinically significant risk of hemorrhage or fistula.
- Participants with any history of another malignancy within 3 years.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
- Clinically significant cardiovascular disease within 6 months prior to the first dose.
- Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
- History of severe bleeding tendency or coagulation dysfunction.
- History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
- Participants with acute, chronic or symptomatic infections.
- Participants with history of immunodeficiency.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase 1b
Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab. |
Solution for infusion Solution for infusion
他の名前:
|
|
実験的:Phase 2
Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab. |
Solution for infusion Solution for infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events
時間枠:Through end of study and up to approximately 24 months
|
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through end of study and up to approximately 24 months
|
|
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
時間枠:Through 90 days after the last dose of study intervention; Approximately 24 months
|
DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last dose of study intervention; Approximately 24 months
|
|
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
時間枠:Approximately 24 months
|
ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
時間枠:Approximately 24 months
|
The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2. |
Approximately 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
時間枠:Approximately 24 months
|
ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Duration of Response (DOR) per RECIST 1.1 by investigator
時間枠:Approximately 24 months
|
DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 by investigator
時間枠:Approximately 24 months
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Overall Survival (OS)
時間枠:Approximately 24 months
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 24 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
時間枠:Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
|
Pharmacokinetics (PK): Serum concentrations of PF-08634404
時間枠:Up to 24 months
|
Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
|
Incidence of antidrug antibody against PF-08634404
時間枠:Up to 24 months
|
To evaluate immunogenicity of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- C6461013
- 2025-523525-17-00 (Ctis)
- Symbiotic-GI-13 (その他の識別子:Pfizer)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。